OverviewSuggest Edit

Illumina is a company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. It provides a line of products and services for the sequencing, genotyping, and gene expression markets. Illumina technology platforms support the scale of experimentation necessary for population-scale studies, genome-wide discovery, target selection, and validation studies. It offers instruments and consumables, which include reagents, flow cells, and microarrays. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.

TypePublic
Founded1998
HQSan Diego, CA, US
Websiteillumina.com
Employee Ratings4
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)7,700(+6%)
Job Openings880
Revenue (FY, 2019)$3.5 B(+7%)
Share Price (Jun 2021)$430.3(+3%)
Cybersecurity ratingCMore

Key People/Management at Illumina

Francis Desouza

Francis Desouza

Chief Executive Officer
Alex Aravanis

Alex Aravanis

Chief Technology Officer
Juliet Cunningham

Juliet Cunningham

Vice President, Investor Relations
Charles Dadswell

Charles Dadswell

General Counsel
Joydeep Goswami

Joydeep Goswami

Senior Vice President of Corporate Development and Strategic Planning
Phil Febbo

Phil Febbo

Chief Medical Officer
Show more

Illumina Office Locations

Illumina has offices in San Diego, Baltimore, Foster City, Hayward and in 13 other locations
San Diego, CA, US (HQ)
5200 Illumina Way
Baltimore, MD, US
801 W Baltimore St #500
Foster City, CA, US
200 Lincoln Centre Dr
Hayward, CA, US
25861 Industrial Blvd
Madison, WI, US
524 Genomic Dr
San Diego, CA, US
4795 Executive Dr
Show all (19)

Illumina Financials and Metrics

Illumina Revenue

Embed Graph
View revenue for all periods
Illumina's revenue was reported to be $3.54 b in FY, 2019 which is a 6.3% increase from the previous period.
USD

Revenue (Q3, 2020)

794.0m

Gross profit (Q3, 2020)

526.0m

Gross profit margin (Q3, 2020), %

66.2%

Net income (Q3, 2020)

179.0m

EBIT (Q3, 2020)

162.0m

Market capitalization (7-Jun-2021)

62.8b

Closing stock price (7-Jun-2021)

430.3

Cash (27-Sept-2020)

1.8b

EV

62.9b
Illumina's current market capitalization is $62.8 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

2.8b3.3b3.5b

Revenue growth, %

21%6%

Cost of goods sold

926.0m1.0b1.1b

Gross profit

1.8b2.3b2.5b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

782.0m830.0m853.0m846.0m838.0m907.0m859.0m633.0m794.0m

Cost of goods sold

244.0m255.0m256.0m262.0m265.0m259.0m240.0m205.0m268.0m

Gross profit

538.0m575.0m597.0m584.0m573.0m648.0m619.0m428.0m526.0m

Gross profit Margin, %

69%69%70%69%68%71%72%68%66%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.2b1.1b2.0b

Accounts Receivable

411.0m514.0m573.0m

Prepaid Expenses

91.0m78.0m105.0m

Inventories

333.0m386.0m359.0m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

678.0m782.0m990.0m

Depreciation and Amortization

156.0m179.0m188.0m

Inventories

(33.0m)(53.0m)25.0m

Accounts Payable

10.0m45.0m(35.0m)
Quarterly
USDFY, 2017

Revenue/Employee

470.4k

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Show all financial metrics

Illumina Operating Metrics

Illumina's Backlog was reported to be $980m in FY, 2019.
FY, 2017FY, 2018FY, 2019

Backlog

$935 m$909 m$980 m

Patent Applications (US)

473529617

Patents (US)

719709799
Show all operating metrics

Illumina Acquisitions / Subsidiaries

Company NameDateDeal Size
GrailSeptember 21, 2020$8 b
EnancioJuly 14, 2020
BlueBeeJune 17, 2020
Edico GenomeMay 15, 2018$100 m
Conexio GenomicsJanuary 27, 2016
GenoLogicsAugust 04, 2015
NextBioOctober 28, 2013
Liquid LogicJuly 23, 2013$96 m
Verinata HealthJanuary 07, 2013$350 m
BlueGnome LtdSeptember 19, 2012
Show more

Illumina Revenue Breakdown

Embed Graph

Illumina revenue breakdown by business segment: 67.5% from Consumables, 15.2% from Instruments and 17.3% from Service and other revenue

Illumina revenue breakdown by geographic segment: 26.3% from Europe, Middle East, and Africa, 10.5% from Greater China, 55.6% from Americas and 7.6% from Asia-Pacific

Human Capital Metrics

Embed Graph
Show all human capital metrics

Illumina Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Illumina Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Illumina Online and Social Media Presence

Embed Graph

Illumina Company Culture

  • Overall Culture

    A+

    79/100

  • CEO Rating

    A+

    82/100

  • Compensation

    A-

    78/100

  • Diversity

    A+

    82/100

Learn more on Comparably

Illumina News and Updates

Global Next Generation Sequencing (NGS) Market Report 2021-2026 Featuring Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies & Roche

Dublin, June 04, 2021 (GLOBE NEWSWIRE) -- The "Global Next Generation Sequencing (NGS) Market (By Products - Consumables, Platforms, Services, Sequencing Services, Bioinformatics, Technology, Applications, End Users, Regions), Impact of COVID-19, Recent Developments, Key Company Profiles - Forecas…

Insights on the Liquid Biopsy Global Market to 2028 - Featuring Qiagen NV, Biocept and Illumina Among Others

Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market by Clinical Application, Therapeutic Application, Biomarker Type, Analysis Platform, Analysis Purpose, Product, Industry Verticals, and Geography - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering…

Insights on the Metagenomic Sequencing Global Market to 2027 - Featuring BGI, Illumina and PerkinElmer Among Others

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Metagenomic Sequencing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Metagenomic Sequencing estimated at US$1.1 Billion in the year 2020, is proje…

What’s Next For Illumina Stock After The Recent 7% Drop?

Despite a Q1 beat, Illumina has seen its share price decline over the last week (five trading sessions). The only negative from the earnings announcement was the margin contraction. Illumina has been investing more into R&D and its SG&A expenses also rose in Q1, pushing the overall operating…

Insights on the Liver Cancer Diagnostics Global Market to 2027 - Featuring Hologic, Illumina & Koninklijke Philips Among Others

Dublin, April 16, 2021 (GLOBE NEWSWIRE) -- The "Liver Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Liver Cancer Diagnostics estimated at US$30.3 Million in the year 2020, i…
Show more

Illumina Frequently Asked Questions

  • When was Illumina founded?

    Illumina was founded in 1998.

  • Who are Illumina key executives?

    Illumina's key executives are Francis Desouza, Alex Aravanis and Juliet Cunningham.

  • How many employees does Illumina have?

    Illumina has 7,700 employees.

  • What is Illumina revenue?

    Latest Illumina annual revenue is $3.5 b.

  • What is Illumina revenue per employee?

    Latest Illumina revenue per employee is $460.1 k.

  • Who are Illumina competitors?

    Competitors of Illumina include Qiagen, Luminex and BGI Genomics.

  • Where is Illumina headquarters?

    Illumina headquarters is located at 5200 Illumina Way, San Diego.

  • Where are Illumina offices?

    Illumina has offices in San Diego, Baltimore, Foster City, Hayward and in 13 other locations.

  • How many offices does Illumina have?

    Illumina has 19 offices.